Here are five takeaways.
1. Stryker’s net sales increased 9.7 percent year-over-year, generating $3.2 billion in sales.
2. In its orthopedics segment, Stryker reported a 7.1 percent increase in sales year-over-year, with 4.7 percent being organic. Net sales totaled $1.2 billion for the quarter.
3. Within the medsurg segment, Stryker reported a 9.3 percent increase in sales year-over-year, with 7.8 percent being organic and 1.3 percent being through acquisitions. Net sales totaled $1.4 billion for the quarter.
4. Stryker’s neurotechnology and spine segment experience the largest growth, as expect. The company reported a 16.1 percent increase in sales year-over-year, with 3.4 percent through acquisitions and 10.1 percent organically. Net sales totaled $600 million for the quarter.
5. Based on it’s first quarter performance, Stryker expects its second quarter diluted earnings per share to be between $1.70 to $1.75.
More articles on devices and implants:
Jury sides with spine surgeon in case of off-label use of Medtronic’s Infuse: 6 things to know
Zimmer Biomet reports a 2.3% jump in sales, spine segment generates $183M: 5 Q1 details
CoreLink appoints David Castleman 1st VP of research and development: 5 things to note
